Researchers Identify Potential Combination Therapy for Ovarian Cancer

Researchers Identify Potential Combination Therapy for Ovarian Cancer
Melding epigenetic inhibitors with the calpain inhibitor calpeptin may be a promising combination therapy approach to treat ovarian cancer patients, including those who are resistant to platinum-based chemotherapy, a new AntiCancer Research study suggests. The study, "The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells," revealed that treating ovarian cancer cells with suboptimal doses of sodium butyrate, SAHA, and calpeptin, has a synergistic effect in tumor cell growth inhibition and tumor cell death. Ovarian cancer is the most deadly cancer of the reproductive system, in part because it is often detected in an advanced state, where the cancer cells have already spread whithin the pelvis and abdomen. Platinum-based chemotherapy has been the mainstay for the past four decades in the treatment of ovarian cancer, regardless of the cancer subtype, mutational status, or biomarkers, but patients often develop resistance to such drugs, revealing the need for novel treatment approaches. In recent years, epigenetics has been proposed as a new target to overcome drug resistance. Epigenetics are modifications in the DNA that do not change its sequence, but that determine which genes will be expressed by which cells at any given time. Since all cells in an organism share the same DNA sequence, epigenetics is what determines that a liver cell is a liver cell, and not a lung cell, for example. The authors of this study had previously shown that epigenetics play a major role in the formation of cancer
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *